Quarterly report pursuant to Section 13 or 15(d)

License and Collaboration Agreements, Nyxol License Agreement (Details)

v3.23.2
License and Collaboration Agreements, Nyxol License Agreement (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Nov. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Performanceobligation
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Performanceobligation
Jun. 30, 2022
USD ($)
Nov. 06, 2022
USD ($)
Collaboration and License Agreement [Abstract]            
Revenue recognized   $ 3,674,000 $ 0 $ 5,423,000 $ 0  
Reconciliation of Closing Balance of Contract Asset [Abstract]            
Beginning Balance       3,552,000    
Revenue recognized   3,674,000 $ 0 5,423,000 $ 0  
Ending Balance   $ 2,595,000   $ 2,595,000    
Nyxol License Agreement [Member]            
Collaboration and License Agreement [Abstract]            
Non-refundable cash payment received $ 35,000,000          
Maximum amount of payments receivable for development, regulatory and commercial milestones           $ 130,000,000
First potential payments to be received           $ 10,000,000
Maximum percentage of tiered royalties receivable   20.00%   20.00%    
Number of distinct performance obligations | Performanceobligation   2   2    
Aggregate transaction price to be recognized       $ 40,000,000    
Period of non-cancellation window agreement       120 days    
Non-cancellation period of constrained       120 days    
Revenue recognized   $ 3,700,000   $ 5,423,000    
Reconciliation of Closing Balance of Contract Asset [Abstract]            
Beginning Balance       3,552,000    
Revenue recognized   3,700,000   5,423,000    
Ending Balance   $ 2,595,000   2,595,000    
Nyxol License Agreement [Member] | License Transfer Fee [Member]            
Collaboration and License Agreement [Abstract]            
Aggregate transaction price to be recognized       35,000,000    
Estimated standalone selling price for license agreement       287,800,000    
Transaction price allocation of ESSP obligations       39,300,000    
Reconciliation of Closing Balance of Contract Asset [Abstract]            
Reclassification to accounts receivable related to costs billed under the Nyxol License Agreement       (6,380,000)    
Nyxol License Agreement [Member] | Research and Development Services [Member]            
Collaboration and License Agreement [Abstract]            
Aggregate transaction price to be recognized       5,000,000    
Estimated standalone selling price for license agreement       5,000,000    
Transaction price allocation of ESSP obligations       700,000    
Nyxol License Agreement [Member] | Sales Milestones [Member]            
Collaboration and License Agreement [Abstract]            
Revenue recognized       0    
Reconciliation of Closing Balance of Contract Asset [Abstract]            
Revenue recognized       $ 0